Skip to main content
. 2018 Dec 6;115(52):13240–13245. doi: 10.1073/pnas.1810897115

Fig. 5.

Fig. 5.

PT2399 treatment reduces fatty liver symptoms only in WT mice fed HFD. WT and KI mice fed HFD for 12 wk were administered vehicle or 30 mg/kg PT2399 twice a day for the final 8 wk. HE staining of liver tissues (A) and liver TG levels (B) from WT and KI mice. (Magnification: A, 200×.) (C) Relative liver DAG and TAG levels in WT and KI mice (n = 4 per group). (D) qPCR analysis of lipid metabolism genes in the liver. (E) Serum TG levels of WT mice. (F) TG clearance of WT mice following 7 wk of PT2399 treatment. (G) Serum ALT levels from WT or KI mice. n = 8 per group. Data are presented as mean ± SEM. Significance between every two groups was calculated using unpaired two-tailed Student’s t test. Two-way ANOVA was performed for comparison of two groups over time followed by Sidak’s multiple test. *P < 0.05, **P < 0.01.